天宇股份(300702.SZ):諾得藥業的氯沙坦鉀氫氯噻嗪片獲批上市
格隆匯2月20日丨天宇股份(300702.SZ)公佈,公司全資子公司浙江諾得藥業有限公司(簡稱“諾得藥業”)於近日收到國家藥品監督管理局核准簽發的關於氯沙坦鉀氫氯噻嗪片兩個規格的《藥品註冊證書》。氯沙坦鉀氫氯噻嗪片是用於治療高血壓,適用於聯合用藥治療的患者。
據統計,2021年氯沙坦鉀氫氯噻嗪片在國內樣本醫院(包括城市公立醫院,城市社區醫院,縣級公立醫院,鄉鎮衞生院)和城市實體藥店的銷售額約人民幣18.7億元(數據來源於米內網)。
諾得藥業氯沙坦鉀氫氯噻嗪片於2021年12月獲得國家藥監局受理,截止目前公司及子公司累計研發投入約1152.12萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.